Inspire(US:INSP) Prnewswire·2025-12-11 20:20Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about the operational readiness of its new device, Inspire V, leading to significant financial losses for investors [1][2]. Summary by Relevant Sections Allegations of Misleading Information - Inspire Medical allegedly assured investors of its "operational readiness" for the Inspire V launch, claiming it was ready for full commercial rollout, which concealed critical operational failures [2][4]. - The lawsuit highlights that the necessary software updates for Medicare claims processing did not take effect until July 1, 2025, delaying the rollout and revenue generation [3]. - There was a significant surplus of the older Inspire IV device, which impacted demand for the new Inspire V product, leading to a drastic cut in 2025 EPS guidance by over 80% [3]. Financial Impact - The stock price of Inspire Medical dropped by $42.04 per share, representing a 32.4% decline in value following the revelation of these operational issues [3]. - The lawsuit claims that many treatment centers had not completed the essential training and onboarding required to implant the new device, further complicating the launch [3]. Legal Actions and Investor Rights - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the January 5, 2026, Lead Plaintiff Deadline to discuss their legal rights [2][4]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, including the Medicare claims software failure and the inventory glut of the prior device [4].